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Background: Massively parallel DNA sequencing (MPS) has the potential to revolutionize diagnostics, in particular
for monogenic disorders. Inborn errors of metabolism (IEM) constitute a large group of monogenic disorders with
highly variable clinical presentation, often with acute, nonspecific initial symptoms. In many cases irreversible
damage can be reduced by initiation of specific treatment, provided that a correct molecular diagnosis can be
rapidly obtained. MPS thus has the potential to significantly improve both diagnostics and outcome for affected
patients in this highly specialized area of medicine.
Results: We have developed a conceptually novel approach for acute MPS, by analysing pulsed whole genome
sequence data in real time, using automated analysis combined with data reduction and parallelization. We applied
this novel methodology to an in-house developed customized work flow enabling clinical-grade analysis of all IEM
with a known genetic basis, represented by a database containing 474 disease genes which is continuously
updated. As proof-of-concept, two patients were retrospectively analysed in whom diagnostics had previously been
performed by conventional methods. The correct disease-causing mutations were identified and presented to the
clinical team after 15 and 18 hours from start of sequencing, respectively. With this information available, correct
treatment would have been possible significantly sooner, likely improving outcome.
Conclusions: We have adapted MPS to fit into the dynamic, multidisciplinary work-flow of acute metabolic
medicine. As the extent of irreversible damage in patients with IEM often correlates with timing and accuracy of
management in early, critical disease stages, our novel methodology is predicted to improve patient outcome.
All procedures have been designed such that they can be implemented in any technical setting and to any genetic
disease area. The strategy conforms to international guidelines for clinical MPS, as only validated disease genes are
investigated and as clinical specialists take responsibility for translation of results. As follow-up in patients without
any known IEM, filters can be lifted and the full genome investigated, after genetic counselling and informed
consent.
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Massively parallel DNA sequencing (MPS) is revolution-
izing diagnostics of inherited diseases, and whole-exome
sequencing (targeted capture and sequencing of all cod-
ing parts of the genome, WES) has recently entered the
clinic [1]. Interrogation of all protein-coding genes re-
sults in a high diagnostic yield, but also leads to identifi-
cation of genetic variants of unclear relationship with the
disease under investigation as well as secondary (inciden-
tal) findings. Clinical WES therefore requires thorough
genetic counseling to prepare subjects for unexpected
findings and to explain results. An alternative approach
focuses on subsets of monogenic disorders, enabled by
filtering of exome data against a panel of selected mono-
genic disease genes. With a targeted exome approach, the
risk for unexpected and secondary findings is greatly re-
duced and interpretation of results is facilitated. This
conforms to guidelines for genetic testing in children [2],
which recommend that analysis is limited to the parts of
the genome relevant to an individual patient’s presen-
tation, as well as to international recommendations for
next-generation sequencing in clinical practice [3,4].
More recently, whole genome sequencing (WGS) has
been used for clinical diagnostics, exploiting the fact that
targeted capture prior to sequencing is circumvented,
resulting in shorter turnaround times. A strategy was re-
cently described, adopted for neonatal intensive care
units (NICUs) [5], enabling 50-hour differential diagno-
sis of genetic disorders by WGS. This short turnaround
time was achieved by technical improvements in sample
preparation and sequencing in combination with deve-
lopment of an automated correlation tool for prioritization
of clinical information to assist interpretation, and fo-
cused on analysis of 591 monogenic diseases with early
pediatric presentation.
We report a principally novel approach for clinical
WGS based on pulsed analysis. By analyzing pulsed
whole genome sequence data in real time, using auto-
mated analysis combined with data reduction and
parallelization, we show that clinical diagnosis of genetic
disorders can be obtained within 15–36 hours. We have
applied this rapid pulsed WGS to an in-house developed
customized workflow enabling comprehensive diagnosis
of all inborn errors of metabolism (IEM) with a known
genetic basis, currently represented by 474 genes in our
Centre for Inherited Metabolic Diseases (CMMS) Inborn
Error of Metabolism gene database (dbCMMS). We have
previously validated this diagnostic platform on whole
exome data, with an overall diagnostic yield of 60%,
using a non-pulsed analysis workflow. For optimal clin-
ical benefit, we have established a collaborative team
consisting of experts in pediatrics, neurology, endoc-
rinology, clinical genetics, biochemistry, neuroimaging,
dietary treatment and bioinformatics, enabling rapidtranslation of WGS data directly into individualized clin-
ical treatment even in acute situations. As survival and
extent of irreversible brain damage critically depend on
time to treatment in acute-onset IEM, this approach has
the potential to significantly increase survival and reduce
neurological sequelae in affected patients. As a proof-of-
concept, two patients who had presented with acute
onset neonatal IEM were retrospectively analyzed in a
blinded trial with no supplied information on the pa-
tient’s phenotypes. The correct disease-causing muta-
tions were identified and presented to the clinical team
15 and 18 hours after start of sequencing, respectively. A
third patient who presented during the investigation was
also analyzed, with negative findings but allowing assess-
ment of 99% of all exonic bases of the 474 disease genes,
making an acute IEM unlikely. In agreement with this
finding, extended clinical investigations and analysis of
the full exome have been negative and the patient re-
mains without a specific diagnosis.Results
The Mutation Identification Pipeline (MIP) [6] together
with dbCMMS and the in-house developed software
Scout, for visualization of clinical variants, constitute a
customized analytical platform designed to enable the
adoption of MPS in a clinical setting, meeting health-
care requirements and conforming to international
guidelines [2-4]. The platform can be adapted to any se-
lection of disease-genes or genomic regions of interest,
by substituting dbCMMS with other customized genes
or genomic regions. In this study we focused on IEM, a
disease area where rapid diagnostics and treatment have
dramatic impact on patient outcome, and where we have
established an expert center containing all clinical ex-
pertise required for rapid translations of findings into in-
dividualized treatment. Using this platform we screened
all 474 known IEM-causing genes for pathogenic muta-
tions in two patients who had presented with acute dis-
ease typical for IEM, in a blinded retrospective study.
We also screened one undiagnosed acute patient who
presented during the investigation.Rapid WGS analysis
In the blinded retrospective analysis of two children with
diagnoses that had previously been established by con-
ventional diagnostics, rapid pulsed WGS followed by our
pipeline consisting of MIP, dbCMMS, Chanjo and Scout,
resulted in presentation of the correct pathogenic vari-
ants in both cases. These could be identified, by the
investigator even without guidance of the patient’s phe-
notypes, for all pair-end pulses and ranked highest ac-
cording to disease causing potential in each clinical
candidate variant list. This illustrates the strength of the
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which are presented to the clinical team for evaluation.
The highest scoring variant for Patient 1 was found in
the gene PCCB encoding for the protein propionyl-CoA
carboxylase, beta chain involved in the propionyl-CoA
degradation pathway. The nonsynonymous homozygous
variant c.1313C > T is very rare, positioned in a con-
served region of the genome and the resulting p.Ala458-
Val amino acid change is predicted to cause loss of
protein function. This homozygous variant had been
confirmed as diagnostic in the patient by Sanger sequen-
cing at 2 months of age, as the mutation is an estab-
lished cause of propionic academia [7]. The rapid pulsed
WGS test presented the correct pathogenic variant after
15 hours from the start of sequencing preparation in this
patient.
An X-linked nonsynonymous variant, c.904C > T, in
the PDHA1 gene was ranked highest in Patient 2. PDHA1
encodes the Pyruvate dehydrogenase E1 component sub-
unit alpha, which catalyzes the conversion of pyruvate to
acetyl-CoA and CO2. The variant is described as patho-
genic in the common public variant databases. The vari-
ant affects four transcripts of PDHA1 but always gives
rise to a p.Arg302Cys amino acid change, predicted to be
damaging for protein function. This variant had been
found diagnostic in the patient by Sanger sequencing at
25 days of age after extensive biochemical investigations.
This had established the diagnosis, as the variant is a
known, recurring cause of pyruvate dehydrogenase de-
ficiency [8]. The rapid pulsed WGS test presented the
correct disease-causing mutation in this patient after
18 hours from the start of sequencing preparation.
Prospective analysis of Patient 3 did not result in any
diagnostic variants in dbCMMS. However, we were able
to assess 468 and 640 candidate genes and correspond-
ing Consensus CDS project transcripts [9], respectively,
making an acute IEM unlikely.
Bioinformatic and pulsed analysis performance
An automated and integrated workflow enabled a first
preliminary diagnosis ~15 hours from DNA isolation. The
sequential pulsed analysis is able to augment this first pre-
liminary report through reanalysis using: (i) longer reads
and (ii) paired-end (PE) reads as the sequencing run pro-
gresses. The identified pathogenic mutations were first
identified in pulse 1 (single-end (SE) 35 nucleotide (nt)
reads) for Patient 1 after approximately 15 hours and in
pulse 2 (SE 50 nt reads) for Patient 2 after approximately
18 hours. Subsequent analysis pulses using longer reads
and PE data all strengthened the initial findings. All ana-
lyzed pulses identified the pathogenic mutations and
ranked them at the top of the respective clinical can-
didate list, except for the initial SE 35 nt reads pulse
for Patient 2, which was unable to identify the causalmutation, due to lack of read depth. The final pulse (PE
100 nt reads) was finished within 36 hours of DNA isola-
tion for all patients (Figure 1).
MIP performs the bioinformatics analysis from raw se-
quences to biologically relevant, annotated and ranked
variants for the final pulse in approximately 4 hours
(Figure 2; other PE pulses [see Additional file 1: Figure S1]).
This rapid data analysis is accomplished by using a
parallelization and data reduction scheme aligning all
reads to the whole human genome and selecting only
data mapping to the exome (or any other user defined
region), after the initial alignment step. This novel
approach significantly reduces the computational load on
downstream processes - substantially speeding up the
analysis. The parallelization also ensures that the align-
ment can be performed efficiently and independently of
the depth of sequencing - as the number of nodes scales
with the amount of generated sequence data. However,
no more than 19 nodes (8 cores per node) in the align-
ment step of any pulse were used in this study. The vari-
ant identification and accuracy are naturally quite poor
for the first analysis pulse but improves progressively
with each additional pulse. However, 99% of called vari-
ants in SE pulse 35 and 50 are reproduced in the final PE
pulse, showing the quality of variants in early pulses. The
observed transition:transversion ratio and heterozygote:
homozygote ratio for the final pulse agree well with the
published range of 2.8-3.1 for human exomes and 1.25-1.7
for European ethnicity, respectively [10] [see Additional
file 2]. The SNP concordant rate with dbSNP129 is
greater than 99.7%, demonstrating the high quality of
identified variants. The coverage metrics completeness
(width and read depth), and diagnostic yield (number of
transcripts fully covered at 10x read depth) for dbCMMS
and the exome are shown in [see Additional file 3]. The
percentage of bases with adequate read depth (to be eval-
uated in the clinical test) for dbCMMS exons is 83, 96,
and 99 for Patients 1, 2 and 3, respectively.
Discussion
The last few years have seen a paradigm shift in the in-
vestigation of inherited disorders, due to technical ad-
vances in DNA sequencing. This has tremendous impact
for diagnostics, particularly of single-gene disorders.
Inborn errors of metabolism comprise a large number
of monogenic disorders disrupting metabolic pathways.
Around 500 different IEM-causing genes are known,
causing deficient function of e.g., carbohydrate, amino
acid, lipid metabolism or mitochondrial oxidative phos-
phorylation. Clinical presentation varies widely and
ranges from acute, neonatal disease to chronic progres-
sive and intermittent forms sometimes presenting as late
as in adult life. Any combination of organs can be af-
fected and patients thus show up across most clinical
Figure 1 Pulse distribution and completion. Timing of pulsed analysis flow from sequencing library preparation to clinical diagnosis. The
amount of time spent on each step is only shown for the final evaluation pulse. WGS: whole genome sequencing, SE: single-end, PE: paired-end.
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cific, diagnosis is challenging and screening methods
need to be employed on wide indications in order to de-
tect patients at early disease stages. Many IEM are treat-
able, either by general support including protein and fat
restriction to remove potentially toxic substrates, glucose
infusion to block catabolism reducing potentially toxic
intermediates and to prevent cellular energy deficiency,
and administration of a cocktail of vitamin cofactors es-
sential for a range of enzymes; or by specific treatment
to remove critical compounds or provide essential sub-
strates once the correct diagnosis is established. There is
also an intense development of small molecule drugs
and recombinant enzyme therapies in this area. ForFigure 2 MIP’s rapid analysis processing time. Cumulative processing timany conditions, the extent of brain damage and neuro-
logical sequelae in affected patients correlate directly
with timing and accuracy of management in early, crit-
ical disease stages. Serial genetic testing is diagnostic in
a minority of IEM cases, since the number of potentially
responsible disease genes is large even when initial clin-
ical and biochemical evaluations have homed in on spe-
cific metabolic pathways.
For the reasons described above, IEM represents a
disease area, which benefits immensely from clinical im-
plementation of MPS. For optimal translation into indi-
vidualized treatment, a cross-disciplinary infrastructure
is needed within this highly specialized area of clinical
medicine. The Centre for Inherited Metabolic Diseasesme for the sequence analysis at the final pulse (PE 100 nt reads).
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lished a cross-disciplinary team of clinical specialists in
metabolic medicine, paediatrics, neurology, endocrinology,
clinical genetics, biochemistry, and bioinformatics. Inten-
sive care units (ICU), neuroimaging specialists, metabolic
clinicians and dieticians are available within the same
hospital. CMMS serves more than half of the Swedish
population with laboratory investigations and expert ad-
vice in cases with suspected IEM. Since 1965, CMMS
also performs the nation-wide neonatal screening pro-
gram (“PKU test”), currently comprising 24 different,
treatable conditions. There is thus a long-standing, broad
experience in diagnosis and management of IEM.
We have previously used our diagnostic platform com-
prising MIP, dbCMMS, Scout and Chanjo [11] (in-house
developed software for coverage calculations of genomic
features) on non-pulsed whole exome data (unpub-
lished). In the initial analyses of previously unsolved
cases with a high suspicion of IEM based on clinical and
biochemical findings, 8/30 (27%) were immediately diag-
nostic, establishing the robust performance of the plat-
form (Additional file 1: Table S1). For patients who were
negative in this clinical IEM test, we proceeded to inves-
tigate the full exome, and identified an additional 10
likely novel disease genes, for which functional valid-
ation is ongoing. We have thus validated the platform
and established its robustness both for clinical diagnos-
tics and for scientific investigations in this selected pa-
tient group, with an overall yield of 60%. Importantly,
we clearly separate the clinical diagnostic and the research
settings, in order to avoid incidental findings and delays in
data interpretation of the clinical test, where a rapid turn-
around time is essential. Extended, full exome analysis is
only performed after thorough genetic counseling and re-
quires written informed consent. This procedure is in full
agreement with ethical guidelines for genetic testing in
children [2] and follows international recommendations
for next-generation sequencing in clinical practice.
As described in this report, we next applied our diagnos-
tic platform to address acute onset cases by developing
rapid pulsed WGS. As proof-of-concept, we retrospect-
ively analyzed two cases that had presented with classic
acute, neonatal-onset IEM in a blinded trial without
guidance of the patients' phenotypes.
Patient 1 suffered from propionic aciduria (PA), one of
a group of organic acidurias. PA is caused by deficiency
of the mitochondrial enzyme propionyl-CoA carboxylase
(PCC), which is required for metabolism of the four
amino acids valine, isoleucine, methionine and threonine
and of odd-chain fatty acids. PCC is a multimeric protein
composed of α and β subunits encoded by the PCCA
and PCCB genes, respectively. The enzyme is biotin-
dependent, and a few patients may respond to biotin
treatment. PA usually presents clinically as a severeneonatal onset form with ketoacidotic coma, hyperam-
monemia and convulsions. There are also late-onset and
intermittent forms. Patients should follow a very strict
diet with limited protein intake and optimized amino acid
preparations. Treatment also includes carnitine and alter-
nated cures of antibiotics to reduce intestinal bacteria
which produce propionic acid. Patients are at risk of acute
decompensation at times of metabolic stress. Early initi-
ated treatment and close monitoring is essential to avoid
death, minimize complications such as psychomotor re-
tardation, cardiomyopathy, and acute pancreatitis.
Diagnosis is conventionally made by chromatography
of urinary organic acids and plasma acylcarnitines to de-
tect propionic acid and other derived products. This al-
lows for a rapid biochemical diagnosis, which is possible
only in a small number of IEM that result in accumula-
tion and secretion of highly specific compounds. The
condition can also be identified by newborn screening,
by detection of propionyl carnitine on dried filter-paper
bloodspots using tandem mass spectrometry. Results
from newborn screening are available around day 7 (me-
dian), which is sometimes too late to prevent brain dam-
age or even death in severe forms of PA. Conventionally,
the diagnosis is confirmed by mutation analysis of the
PCCA and PCCB genes. As described, rapid pulsed WGS
indicated the correct diagnosis after 15 hours in Patient 1.
Patient 2 had primary lactic acidosis, an acute neonatal
condition resulting from circulatory failure, septicaemia
or indicating a severe underlying metabolic dysfunction.
Several IEM can be responsible, including e.g., pyruvate
dehydrogenase deficiency (PDHD), pyruvate carboxylase
deficiency, defects of gluconeogenesis and a wide range
of mitochondrial diseases. All these metabolic disorders
are genetically heterogeneous. For example, six subtypes
of PDHD have been recognized. The most common
PDHD results from mutations in the X-linked PDHA1
gene, which encodes the E1-alpha subunit of the enzyme
complex. Unlike most X-linked enzyme deficiencies, this
disease frequently causes severe symptoms in heterozy-
gous females.
The PDH complex is essential by transforming pyruvate
generated by glycolysis into acetyl-CoA, which may then
be used in the citric acid cycle to generate energy and ul-
timately enable ATP synthesis by the respiratory chain.
The symptoms of PDHD are thus due to bioenergetic defi-
ciency together with lactic acidosis. Manifestations range
from fatal, severe, neonatal disease to later-onset neuro-
logical disorders and symptoms are aggravated by carbo-
hydrate intake.
Diagnosis is conventionally made by demonstrating ab-
normal enzyme function in cultured cells, measurements
of ATP production in isolated muscle mitochondria using
pyruvate as a substrate, and/or genetic analysis. Treat-
ment aims at stimulating the PDH complex by cofactor
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tients with mutations in the PDHA1 gene are thiamine-
responsive. A ketogenic diet is used to provide an alter-
native source of energy than carbohydrates, particularly
for the brain, and dichloroacetate can be used to reduce
elevated lactate levels. Prognosis is variable but is gener-
ally poor in severe cases, and depends critically on early
initiation of treatment. Careful monitoring is essential to
minimize the risk of metabolic decompensation.
Glucose infusion is a standard acute treatment in sus-
pected IEM before a specific diagnosis has been es-
tablished, since successful treatment in most conditions
critically depends on interrupting catabolism, reducing in-
take of protein and fat, and supplying energy. This can re-
sult in lactic acidosis and careful monitoring of lactate is
required. With access to results from rapid pulsed WGS
after 18 hours, specific treatment including a ketogenic diet
would have been started several days earlier in Patient 2,
likely preventing large parts of the patients' brain damage.
The above two examples illustrate typical situations in
acute metabolic medicine. Due to the large number of
IEM and their nonspecific initial presentations, acute
treatment is nonspecific and aims at preventing further
damage while diagnostic workup proceeds to succes-
sively direct treatment into the right direction. As serial
gene testing only can cover a fraction of all known
disease genes, workup includes e.g., measurements of
metabolites in body fluids, specific enzyme assays in iso-
lated cells, and/or investigations of respiratory chain
function after isolation of mitochondria from a muscle
biopsy. It may be weeks before a specific diagnosis is ul-
timately obtained in successful cases and individualized
treatment can be initiated. Importantly, many patients
never receive a specific molecular diagnosis even though
they suffer from a previously described but rare IEM.
The pulsed analysis opens up the possibility of a first
clinical assessment of sequence variants in hundreds of
relevant genes after only ~15 hours from the start of
WGS, although the variant sensitivity and accuracy at
this stage is quite poor. In this context, preliminary dis-
closure is highly acceptable as it directs further investi-
gations into the right direction and aids in the choice of
treatment. Results from MPS thus form an integrated
part of the clinical workup where multiple parameters
are followed by the clinical team, and management is
continuously optimized until the situation is stable and
data are robust. MPS has thus been adapted so it fits
into the dynamic, multidisciplinary work-flow of acute
metabolic medicine. As a result, a ketogenic diet could
have been initiated several days earlier in Patient 2, likely
reducing neurological sequelae substantially. Despite the
limitations in quality of the preliminary data, it was still
sufficient to identify the causal mutations in pulse 1 for
Patient 1 and in pulse 2 for Patient 2. After the firstpulse, data successively improve and Sanger sequencing
is used to confirm the individual mutations.
Although we were unable to identify the causal muta-
tion for Patient 3 we were able to fully assess 95% of
Collaborative consensus coding sequencing project
(CCDS) transcripts and in total evaluate 99% of exonic
bases (including splice dinucleotides) included in the
clinical test (dbCMMS). Hence, these are unlikely to har-
bor the causal mutation and constitute important nega-
tive findings. These results are in agreement with the
extended clinical evaluations of this patient, which have
failed to provide an explanation for the patients' illness
despite months of follow-up. Mining the full exome of
this patient has also failed to identify a likely monogenic
cause of the patients' illness.
In this study, we have shortened the time to results
from a standard WES and WGS in a clinical setting
from at least a month to a first preliminary clinical re-
port after 15 hours and a final report after 36 hours.
These improvements were made possible by (i) the
modification to the data extraction scheme of the widely
used Illumina Hiseq 2500 instrument that enabled se-
quencing of a human genome in less than 30 hours and
(ii) pulsed automated analysis and (iii) data selection
using a clinically predefined subset of genes, in this
study dbCMMS, and (iv) using an in-house developed
workflow of automated sequence analysis (MIP), assess-
ment of coverage and diagnostic yield (Chanjo) and
visualization and interpretation (Scout).
MIP handles all laborious tasks in the MPS analysis,
while the clinical evaluation of the results is performed
interactively in Scout, which holds information essential
for variant interpretation such as allele frequencies, inher-
itance patterns, predicted effects on protein function, and
links to external databases. This user-friendly visualization
tool greatly facilitates clinical translation. The variant
sensitivity and accuracy are poor for early pulses, but was
sufficient to identify the causal mutation in both retro-
spective patients examined. The exonic variant quality
for the complete run is indistinguishable from a “stand-
ard” WGS analysis [see Additional files 2 and 3] but ac-
complished in only ~4 hours compared to the standard
procedure of: alignment, realignment, recalibration; vari-
ant identification and recalibration; and variant annota-
tion; which takes approximately 1 week.
Further improvements to the automatic analysis in
terms of speed, sensitivity and accuracy are expected as
both computer power and the underlying algorithms are
continuously improving. We have also not tested omit-
ting some of the recalibration steps used in the analysis
for greater speed. It is at present unclear how this would
affect the overall false positive and negative rates.
We have found our diagnostic platform for IEM to be
efficient and reliable, as it quickly generates decisive,
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or secondary (incidental) findings. Due to this robust per-
formance, the test can be scaled up substantially. The
addition of rapid pulsed WGS represents a further dra-
matic diagnostic improvement. Since initial symptoms of
IEM are nonspecific, these tests need to be employed on
wide indications, for timely diagnosis of IEM as well as for
directing clinical investigations in other directions for
patients with other causes behind their illness. However,
despite the fact that the overwhelming majority of all
disease-causing mutations are located in the protein-
coding parts of our genome [12], like all genetic tests
they are not 100% sensitive. The continued integration of
biochemical and genetic investigations is therefore essen-
tial, in order not to miss atypical cases as well as to valid-
ate genetic variants of unclear functional significance.
A previous study [5], demonstrated a 50-hour differen-
tial diagnosis of genetic disorders by rapid WGS. This
method required well-described clinical phenotypes
broken down into standardized clinical terms that were
automatically matched to selected disease genes, to iden-
tify potentially causal mutations. Our novel pulsed ana-
lysis reduces turnaround time even further. In addition,
our approach can incorporate any selection of disease
genes or genomic regions in the analysis and uses stand-
ard MPS tools (e.g., BWA, SAMTools and BEDTools)
to achieve its speed, making the data reduction and
parallelization steps easily adoptable in other MPS pipe-
lines. Furthermore, we advocate working with specialized,
multidisciplinary, clinical teams, especially in diagnosis of
treatable disorders where irreversible damage results from
delayed or erroneous treatment. Automated, computer-
based matching of clinical symptoms and disease genes
can aid in diagnostics, but in metabolic medicine, where
disease presentation is nonspecific and a large number of
parameters need to be monitored, and where rapid clin-
ical actions are often required, clinical professionals
working across disciplines are needed for optimal transla-
tion of the high-throughput genetic data all the way into
individualized patient management.
Conclusions
We have applied our novel rapid, pulsed WGS to an in-
house developed customized work flow enabling clin-
ical-grade analysis of all inborn errors of metabolism
(IEM) with a known genetic basis, currently represented
by 474 genes. Using this approach, MPS is adapted so it
fits into the dynamic, multidisciplinary work-flow of
acute metabolic medicine, greatly improving diagnostics
while conforming to ethical guidelines for genetic testing
in children, and to international recommendations for
exome and genome sequencing in clinical practice [3,4].
A cross-disciplinary clinical team has been established,
enabling rapid translation of genetic findings directlyinto individual patient management in this highly spe-
cialized field of clinical medicine. Clinical presentations
of IEM vary widely and early symptoms are nonspecific.
As the extent of brain damage in affected patients often
correlates with timing and accuracy of management in
early, critical disease stages, our novel methodology is
predicted to significantly reduce neurological sequelae
and improve the outcome in affected patients. Our
approach and the tools developed are designed to also
facilitate implementation in other genetic disease areas.
Methods
Patients
Two individuals, Patient 1 and Patient 2 presenting with
classic, acute-onset neonatal IEM, were retrospectively
analyzed. To illustrate the strength of the methodology
in objectively identifying likely pathogenic variants, the
investigators involved in sequencing and data analyses
were not informed of their diagnoses. One acutely ill
child presenting during the preparation of this ma-
nuscript, Patient 3, was prospectively analyzed. The
study was approved by the Regional Ethics Committee
at Karolinska Institutet and written informed consent
was obtained by the guardians of the patients. Because
of the risk of detection of incidental findings not related
to the specific medical conditions under investigation,
and due to the fact that genome sequences are consid-
ered as personal identifiers under the Swedish law, the
IRB precluded public dissemination of the raw genomic
sequences.
Whole genome sequencing
Genomic DNA was isolated from the patients using the
QIAamp DNA blood midi kit (Qiagen) and prepared for
rapid WGS using the TruSeq DNA PCR-Free LT kit
(Illumina). Briefly, sample preparation was performed
with low sample protocol and fragment size 350 bp, all
enzymatic steps and clean up was performed according
to manufacturer's instructions.
Clustering and pair-end sequencing (2 × 100 sequen-
cing by synthesis (SBS) cycles) were performed on a
HiSeq 2500 (Illumina) in RAPID run mode using on
board cluster generation according to manufacturer's
instructions.
MIP
The pulsed sequence data were analyzed using the Mu-
tation Identification Pipeline (MIP) v1.3 with the rapid
mode setting enabled (Figure 3). MIP is a flexible fully
automated sequence analysis pipeline for pedigrees or
single samples, which handles WES and WGS data. MIP
performs QC of: raw sequences; read mapping; variants,
sample integrity (sex and relationship). MIP supports
any aligner that inputs fastq files and produces SAM or
Figure 3 Sequencing and analysis overview. Summary of steps used in the pulsed automated bioinformatic analysis, resulting in a final clinical
diagnosis within 36 hours. SBS: sequencing by synthesis, Seq: sequencing, Clin: clinical, SE: single-end pulse, PE: paired-end pulse.
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are Mosaik and BWA. BAM file pre-processing, variant
discovery and filtering are performed with GATK. MIP
uses Annovar for standard annotations and also supports
any annotation database that can be split by Perl´s split
function. Thus, the user has full flexibility to include any
annotation on a variant as long as there is a suitable data
file available. MIP annotates the genetic inheritance pat-
tern (including compound mutations) and uses a weighted
sum model to score and rank variants according to disease
causing potential based on a subset of these annotations.
Most weight in the rank score model is put on the inher-
itance pattern, minor allele frequency, gene coding anno-
tation, functional annotation and protein predictions.
Thus, MIP retains all variants but prioritizes them ac-
cording to disease causing potential based on the rank
score. MIP allows for selection of variants overlapping
genetic panels and analysis of specific genomic regions.
MIP [6] is freely and openly available at GitHub.
Chanjo
Chanjo is an in-house developed analysis tool capable of
annotating genomic regions with biological elements e.g.
exons, transcripts, gc-content, and calculating sequence
coverage across these features. Hence, Chanjo can be
used to analyze coverage depth for genomic regions and
features, a requirement for clinical-grade analyses, but
can also shed light on why some genetic regions areunderrepresented by analyzing the associated annotated
features. MIP is used in conjunction with Chanjo to gen-
erate clinical coverage reports. The coverage reports can
be viewed dynamically in a browser or as a static PDF.
Chanjo [11] is freely and openly available at GitHub.
Scout
MIP’s final output i.e., identified, annotated and scored
variants, lays the foundation for Scout. Scout organizes
and prioritizes the massive information content both
from MIP and external resources, providing non-bioin-
formaticians an easy to use graphical interface accessible
via a web browser, and facilitates interpretation and fur-
ther manual analysis.
dbCMMS
dbCMMS is a database of genes annotated with clinical
information that represent IEM with a known genetic
basis, currently represented by 474 genes. dbCMMS has
been assembled from our own clinical data gathered
from over 25 years of clinical experience, by vetting lit-
erature, and public databases. dbCMMS is continuously
updated as novel IEM are discovered.
Sequence analysis
CASAVA v1.8.2 performed demultiplexing and conver-
sion, while the custom script, Pulse_conversion.py [13],
Stranneheim et al. BMC Genomics 2014, 15:1090 Page 9 of 10
http://www.biomedcentral.com/1471-2164/15/1090extracted raw sequence reads during the sequence run
at the predefined SBS cycles: 35, 50, 75 and 100.
Sequence and alignment quality metrics for each pa-
tient and PE pulse are available in Additional file 1:
Table S2-S3. Variant quality metrics for 2 SE pulses are
available in Additional file 1: Table S4. Briefly, the se-
quence reads were aligned to the whole human genome
reference GRCH37 using BWA v0.7.5a [14], while select-
ing only aligned reads mapping to the exome, as defined
by SureSelect Human All Exon V4 (Agilent), for down-
stream analysis using SAMtools [15], BEDTools [16] and
Picard [17]. All coverage metrics were calculated using
Chanjo v0.4 [11]. GATK [18,19] v2.7-2 performed re-
alignment, base recalibration, variant identification, re-
calibration and genotyping. Annovar [20] v2012-10-23
annotated the variants and MIPs custom scripts ranked
them according to pathogenic potential. A summary
of annotations and score parameters are available in
Additional file 1: Table S5. All variants overlapping
dbCMMS v.1.0 were loaded into Scout v1.0 hosted at
SciLifeLab for clinical evaluation.Additional files
Additional file 1: Figure S1. MIP’s rapid analysis processing time. Table
S1. Results from WES using the MIP-dbCMMS-Scout platform in patients
with a high suspicion of IEM. Table S2. Sequence and alignment metrics
final pulse. Table S3. Sequence and alignment metrics PE pulsed SBS
cycles. Table S4. Variant quality metrics metrics SE pulsed SBS cycles.
Table S5. Annotations and score parameters used by MIP in the pulsed
analysis.
Additional file 2: Variant quality metrics (final pulse; exome
variants). 1eval: Evaluated, 2Ts: Transitions, 3Tv: Transversions,
4Het: Heterozygotes, 5Hom: Homozygotes, 6WGS: Whole genome
sequencing, 7WES: Whole exome sequencing, 8All detected variants,
9Detected variants present in dbSNP129.
Additional file 3: Coverage metrics for final pulse. 1Each base
covered to at least 10x in CCDS transcripts, 2CCDS transcripts fully
covered at 10x, 3WGS: Whole genome sequencing, 4WES: Whole exome
sequencing.Competing interests
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